|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lynch TJ, Bell DW, Sordella R, et al:
Activating mutations in the epidermal growth factor receptor
underlying responsiveness of non-small-cell lung cancer to
gefitinib. New Engl J Med. 350:2129–2139. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mitsudomi T, Morita S, Yatabe Y, et al:
Gefitinib versus cisplatin plus docetaxel in patients with
non-small-cell lung cancer harbouring mutations of the epidermal
growth factor receptor (WJTOG3405): an open label, randomised phase
3 trial. Lancet Oncol. 11:121–128. 2010. View Article : Google Scholar
|
|
4
|
Sequist LV, Martins RG, Spigel D, et al:
First-line gefitinib in patients with advanced non-small-cell lung
cancer harboring somatic EGFR mutations. J Clin Oncol.
26:2442–2449. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Rosell R, Moran T, Queralt C, et al:
Screening for epidermal growth factor receptor mutations in lung
cancer. N Engl J Med. 361:958–967. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Mok TS, Wu YL, Thongprasert S, et al:
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N
Engl J Med. 361:947–957. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kobayashi S, Boggon TJ, Dayaram T, et al:
EGFR mutation and resistance of non-small-cell lung cancer to
gefitinib. N Engl J Med. 352:786–792. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Pao W, Miller VA, Politi KA, et al:
Acquired resistance of lung adenocarcinomas to gefitinib or
erlotinib is associated with a second mutation in the EGFR kinase
domain. PLoS Med. 2:e732005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Engelman JA, Zejnullahu K, Mitsudomi T, et
al: MET amplification leads to gefitinib resistance in lung cancer
by activating ERBB3 signaling. Science. 316:1039–1043. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Shien K, Toyooka S, Yamamoto H, et al:
Acquired resistance to EGFR inhibitors is associated with a
manifestation of stem cell-like properties in cancer cells. Cancer
Res. 73:3051–3061. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Young JC, Moarefi I and Hartl FU: Hsp90: a
specialized but essential protein-folding tool. J Cell Biol.
154:267–273. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wright L, Barril X, Dymock B, et al:
Structure-activity relationships in purine-based inhibitor binding
to HSP90 isoforms. Chem Biol. 11:775–785. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Solit DB, Basso AD, Olshen AB, Scher HI
and Rosen N: Inhibition of heat shock protein 90 function
down-regulates Akt kinase and sensitizes tumors to Taxol. Cancer
Res. 63:2139–2144. 2003.PubMed/NCBI
|
|
14
|
Trepel J, Mollapour M, Giaccone G and
Neckers L: Targeting the dynamic HSP90 complex in cancer. Nat Rev
Cancer. 10:537–549. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ueno T, Tsukuda K, Toyooka S, et al:
Strong anti-tumor effect of NVP-AUY922, a novel Hsp90 inhibitor, on
non-small cell lung cancer. Lung Cancer. 76:26–31. 2012. View Article : Google Scholar
|
|
16
|
Shimamura T, Li D, Ji H, et al: Hsp90
inhibition suppresses mutant EGFR-T790M signaling and overcomes
kinase inhibitor resistance. Cancer Res. 68:5827–5838. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Koizumi H, Yamada T, Takeuchi S, et al:
Hsp90 inhibition overcomes HGF-triggering resistance to EGFR-TKIs
in EGFR-mutant lung cancer by decreasing client protein expression
and angiogenesis. J Thorac Oncol. 7:1078–1085. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ha K, Fiskus W, Rao R, et al: Hsp90
inhibitor-mediated disruption of chaperone association of ATR with
hsp90 sensitizes cancer cells to DNA damage. Mol Cancer Ther.
10:1194–1206. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kim WY, Oh SH, Woo JK, Hong WK and Lee HY:
Targeting heat shock protein 90 overrides the resistance of lung
cancer cells by blocking radiation-induced stabilization of
hypoxia-inducible factor-1alpha. Cancer Res. 69:1624–1632. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tse AN, Sheikh TN, Alan H, Chou TC and
Schwartz GK: 90-kDa heat shock protein inhibition abrogates the
topoisomerase I poison-induced G2/M checkpoint in p53-null tumor
cells by depleting Chk1 and Wee1. Mol Pharmacol. 75:124–133. 2009.
View Article : Google Scholar :
|
|
21
|
Arlander SJ, Felts SJ, Wagner JM,
Stensgard B, Toft DO and Karnitz LM: Chaperoning checkpoint kinase
1 (Chk1), an Hsp90 client, with purified chaperones. J Biol Chem.
281:2989–2998. 2006. View Article : Google Scholar
|
|
22
|
Lee JH, Choi KJ, Seo WD, et al:
Enhancement of radiation sensitivity in lung cancer cells by
celastrol is mediated by inhibition of Hsp90. Int J Mol Med.
27:441–446. 2011.PubMed/NCBI
|
|
23
|
Stingl L, Stuhmer T, Chatterjee M, Jensen
MR, Flentje M and Djuzenova CS: Novel HSP90 inhibitors, NVP-AUY922
and NVP-BEP800, radiosensitise tumour cells through cell-cycle
impairment, increased DNA damage and repair protraction. Br J
Cancer. 102:1578–1591. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Gandhi J, Zhang J, Xie Y, et al:
Alterations in genes of the EGFR signaling pathway and their
relationship to EGFR tyrosine kinase inhibitor sensitivity in lung
cancer cell lines. PLoS One. 4:e45762009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Girard L, Zochbauer-Muller S, Virmani AK,
Gazdar AF and Minna JD: Genome-wide allelotyping of lung cancer
identifies new regions of allelic loss, differences between small
cell lung cancer and non-small cell lung cancer, and loci
clustering. Cancer Res. 60:4894–4906. 2000.PubMed/NCBI
|
|
26
|
Kubo T, Toyooka S, Tsukuda K, et al:
Epigenetic silencing of microRNA-34b/c plays an important role in
the pathogenesis of malignant pleural mesothelioma. Clin Cancer
Res. 17:4965–4974. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Rogakou EP, Pilch DR, Orr AH, Ivanova VS
and Bonner WM: DNA double-stranded breaks induce histone H2AX
phosphorylation on serine 139. J Biol Chem. 273:5858–5868. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Das AK, Sato M, Story MD, et al:
Non-small-cell lung cancers with kinase domain mutations in the
epidermal growth factor receptor are sensitive to ionizing
radiation. Cancer Res. 66:9601–9608. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Dittmann K, Mayer C, Fehrenbacher B, et
al: Radiation-induced epidermal growth factor receptor nuclear
import is linked to activation of DNA-dependent protein kinase. J
Biol Chem. 280:31182–31189. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Pawlik TM and Keyomarsi K: Role of cell
cycle in mediating sensitivity to radiotherapy. Int J Radiat Oncol
Biol Phys. 59:928–942. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Koll TT, Feis SS, Wright MH, et al: HSP90
inhibitor, DMAG, synergizes with radiation of lung cancer cells by
interfering with base excision and ATM-mediated DNA repair. Mol
Cancer Ther. 7:1985–1992. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Eccles SA, Massey A, Raynaud FI, et al:
NVP-AUY922: a novel heat shock protein 90 inhibitor active against
xenograft tumor growth, angiogenesis, and metastasis. Cancer Res.
68:2850–2860. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Stecklein SR, Kumaraswamy E, Behbod F, et
al: BRCA1 and HSP90 cooperate in homologous and non-homologous DNA
double-strand-break repair and G2/M checkpoint activation. Proc
Natl Acad Sci USA. 109:13650–13655. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Bakkenist CJ and Kastan MB: DNA damage
activates ATM through intermolecular autophosphorylation and dimer
dissociation. Nature. 421:499–506. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kastan MB and Lim DS: The many substrates
and functions of ATM. Nat Rev Mol Cell Biol. 1:179–186. 2000.
View Article : Google Scholar
|
|
36
|
Lundholm L, Haag P, Zong D, et al:
Resistance to DNA-damaging treatment in non-small cell lung cancer
tumor-initiating cells involves reduced DNA-PK/ATM activation and
diminished cell cycle arrest. Cell Death Dis. 4:e4782013.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Phillips TM, McBride WH and Pajonk F: The
response of CD24(−/low)/CD44(+) breast cancer-initiating cells to
radiation. J Natl Cancer Inst. 98:1777–1785. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Bao S, Wu Q, McLendon RE, et al: Glioma
stem cells promote radioresistance by preferential activation of
the DNA damage response. Nature. 444:756–760. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Oxnard GR, Arcila ME, Chmielecki J,
Ladanyi M, Miller VA and Pao W: New strategies in overcoming
acquired resistance to epidermal growth factor receptor tyrosine
kinase inhibitors in lung cancer. Clin Cancer Res. 17:5530–5537.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Sequist LV, Waltman BA, Dias-Santagata D,
et al: Genotypic and histological evolution of lung cancers
acquiring resistance to EGFR inhibitors. Sci Transl Med.
3:75ra262011. View Article : Google Scholar : PubMed/NCBI
|
